<DOC>
	<DOCNO>NCT02637375</DOCNO>
	<brief_summary>Based preclinical data implicate GR , AR , JAK/STAT activation potent mechanism breast cancer cell survival despite chemotherapy administration ( i.e . chemotherapy resistance ) , study test novel approach improve chemotherapy effectiveness add Hsp90 inhibition antagonize anti-apoptotic signal pathway initiate via GR , AR , JAK/STAT activation .</brief_summary>
	<brief_title>A Pilot Preoperative Trial Ganetespib With Paclitaxel Triple-Negative Breast Cancer</brief_title>
	<detailed_description>STUDY OBJECTIVES Primary : • To determine tumor GR , AR , JAK Hsp90 client protein expression two week ganetespib monotherapy Secondary : - To determine pathological Complete Response ( pCR ) rate associate weekly treatment ganetespib plus paclitaxel follow combination treatment doxorubicin plus cyclophosphamide - To characterize toxicity study treatment</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Invasive carcinoma breast ER negative PR negative tumor define &lt; 1 % tumor nuclei immunoreactive ER PR HER2 nonoverexpressing status document : FISH ratio less 2.0 , OR IHC stain 0 1+ No evidence distant metastatic disease . Patients regional lymph node involvement eligible . &gt; 18 year old Female No prior treatment disease study No prior treatment within 5 year cancer include chemotherapy , surgery ( except diagnostic biopsy ) , radiotherapy , hormonal therapy , investigational agent , unless curative treatment nonmelanoma skincancer insitu cancer Able understand sign inform consent ( legal representative able ) Clinically radiologically measureable disease breast diagnostic biopsy , define long diameter great equal 2cm Willing undergo three mandatory core biopsy diagnosis obtain tissue biologic expression profiling . An Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Adequate bone marrow reserve evidence : Leukocytes &gt; 3,000/μL Absolute neutrophil count ( ANC ) &gt; 1,500/μL without use hematopoietic growth factor , Platelet count &gt; 100,000/μL , Hemoglobin &gt; 9 g/dL Adequate hepatic function evidence : Serum total bilirubin within institutional normal limit Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase less equal 2.5 × ULN Adequate renal function evidence serum creatinine within ULN creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal Eligible treatment paclitaxel , doxorubicin cyclophosphamide If childbearing potential , willing abstain sexual intercourse use effective form contraception ( e.g. , doublebarrier method ) study 90 day follow last dose ganetespib • Patients may receive investigational agent . Patients may know hypersensitivity component ganetespib Patients may history severe allergic reaction paclitaxel drug formulate Cremaphor® EL . Patients QTc &gt; 470 m , family history long QT Syndrome , medication know cause Torsades de Pointes exclude study . Patients may uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients may New York Heart Association ( NYHA ) Class III IV congestive heart failure leave ventricular ejection fraction ( LVEF ) &lt; 50 % . As patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive patient receive combination antiretroviral therapy exclude study . Patients may need chronic systemic steroid therapy Patients may pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>triple-negative breast cancer</keyword>
</DOC>